NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (NASDAQ:QTI), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce an amendment to its $10,000,000 convertible promissory note with YA II PN, Ltd. (the “Investor,” and such promissory note, the “Note”)..

加利福尼亚州诺瓦托市——（商业新闻短讯）——QT Imaging Holdings，Inc.（纳斯达克股票代码：QTI）是一家从事创新人体成像系统研究、开发和商业化的医疗器械公司，很高兴宣布对其与YA II PN，Ltd.（以下简称“投资者”）的10000000美元可转换本票进行修订。。

On September 11, 2024, a trigger event associated with the share price of the company occurred under the terms of the Note. As a result, the company made a payment of $1,500,000 on September 13, 2024, and could have been obligated to make subsequent similar monthly payments. On September 26, 2024, the company and the Investor entered into an amendment of the Note, whereby the parties agreed to amend certain terms of the Note to reduce the company’s monthly payment obligations resulting from the trigger event..

2024年9月11日，根据票据条款，发生了与公司股价相关的触发事件。因此，该公司于2024年9月13日支付了1500000美元，并可能有义务随后每月支付类似款项。2024年9月26日，公司和投资者对票据进行了修订，双方同意修订票据的某些条款，以减少公司因触发事件而产生的每月付款义务。。

The maturity date of the Note was extended approximately 6 months from June 4, 2025, to December 15, 2025. Additionally, the amendment deferred all monthly cash payments due until January 15, 2025, replaced the company’s prior monthly payment obligation of approximately $1,500,000 during a trigger event with an unqualified obligation to make monthly payments of approximately $600,000 beginning on January 15, 2025, and waived the potential delisting of the company’s common stock from Nasdaq as an event of default under the Note..

该票据的到期日从2025年6月4日延长至2025年12月15日约6个月。此外，该修正案将所有到期的月度现金支付推迟至2025年1月15日，将公司之前在触发事件期间约1500000美元的月度支付义务替换为自2025年1月15日起每月支付约600000美元的无条件义务，并放弃了公司普通股作为票据项下违约事件从纳斯达克退市的可能性。。

“On behalf of the QTI leadership team and Board of Directors, I would like to thank the Yorkville team for their partnership and trust, as the execution of this amendment gives the QTI team the runway to successfully execute its first year plan as a public company, where our keen focus remains the successful commercial shipments of our Breast Acoustic CT™ Scanners in the United States,” said Dr.

“我代表QTI领导团队和董事会，感谢Yorkville团队的合作和信任，因为这项修正案的执行为QTI团队成功执行其上市公司第一年计划提供了渠道，我们的重点仍然是我们的乳腺声学CT™扫描仪在美国的成功商业装运，”Dr。

Raluca Dinu, Chief Executive Officer and member of the Board of Directors..

首席执行官兼董事会成员Raluca Dinu。。

About QT Imaging Holdings, Inc.

关于QT Imaging Holdings，Inc。

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience.

QT Imaging Holdings，Inc.是一家上市（纳斯达克股票代码：QTI）医疗器械公司，从事使用低频声波的创新人体成像系统的研究、开发和商业化。QT Imaging Holdings，Inc.致力于改善全球健康状况。它的策略是基于这样一个事实，即医学成像对于疾病的检测，诊断和治疗至关重要，并且它应该是安全的，负担得起的，可获得的，并且以患者的体验为中心。

For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com..

有关QT Imaging Holdings，Inc.的更多信息，请访问该公司的网站www.qtimaging.com。。

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Breast Acoustic CT™是QT Imaging Holdings，Inc.附属公司的商标。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding future payments by QT Imaging Holdings under the Yorkville note, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。此类报表包含“will”和“expect”等词语或其否定词或类似术语，并包括（但不限于）关于QT Imaging Holdings在约克维尔票据下的未来付款、QT Imaging Holdings计划、新产品开发和推出以及产品销售增长和预计收入的报表。

Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the Breast Acoustic CT™ Scanner, the ability of QT Imaging Holdings to sell and deploy the Breast Acoustic CT™ Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels.

。这些风险包括但不限于：使用乳腺声学CT™扫描仪的研究结果，QT Imaging Holdings销售和部署乳腺声学CT™扫描仪的能力，将产品产品扩展到新领域或产品的能力，技术商业化的能力，阻止产品完整记录和“上市”计划的意外事件，行业趋势和波动，客户需求和采购量的变化，供应商的不可预测性，吸引和留住合格人员的能力以及将产品销售提高到生产水平的能力。

Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings' (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC.

可能导致实际结果不同的其他因素在“风险因素”标题下以及QT Imaging Holdings（及其前身GigCapital5，Inc.）向美国证券交易委员会提交的其他部分，以及其不时向美国证券交易委员会提交的其他当前和定期报告中进行了讨论。

All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdin.

本新闻稿中的所有前瞻性声明均基于QT Imaging Holdin可获得的信息，于本新闻稿发布之日做出。